Source comparison
Route of Administration and Bioavailability: IV vs Subcutaneous Dosing
Intravenous administration bypasses hepatic first-pass metabolism and delivers 100% bioavailability, meaning the entire administered dose reaches systemic circulation and can cross the blood-brain barrier to act on hypothalamic GnRH neurons. This is why IV bol
This comparison does not assign a generated winner or score.
- Intravenous administration bypasses hepatic first-pass metabolism and delivers 100% bioavailability, meaning the entire administered dose reaches systemic circulation and can cross the blood-brain barrier to act on hypothalamic GnRH neurons. This is why IV bolus protocols remain the gold standard for dose-finding studies. The pharmacokinetic variability is minimised, and the LH response correlates tightly with the administered dose within the 0.1–1.0 nmol/kg range.
- Subcutaneous kisspeptin requires higher nominal doses (0.5–3.0 nmol/kg) to achieve equivalent LH stimulation because absorption from subcutaneous tissue is incomplete and subject to enzymatic degradation by tissue peptidases before reaching circulation. A 2020 study in Frontiers in Endocrinology compared IV and subcutaneous kisspeptin-54 at matched doses and found subcutaneous administration produced 35–50% lower peak LH levels and delayed time-to-peak by 30–45 minutes. The practical implication: subcutaneous protocols must compensate with dose escalation or accept attenuated LH response.
- Intramuscular administration has been tested in animal models but is rarely used in human studies due to unpredictable absorption kinetics and local tissue irritation. Intranasal kisspeptin formulations are under development but face the challenge of peptide molecular weight (kisspeptin-54 is 5.4 kDa) limiting mucosal absorption. Current data suggests intranasal bioavailability remains below 10%, making it unsuitable for reliable LH stimulation without significant formulation advances.